SAN CARLOS, Calif.--September 23, 2026--Glycomine, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to GLM101 for the treatment of phosphomannomutase 2 congenital...
Mike Grey will be moderating a panel discussion on strategies for CNS drug and device development at the Neurotech Investing and Partnering Conference in San Francisco, CA.
News | 05. 10. 2011
